Hepatitis B x antigen (HBx) is an important therapeutic target in the pathogenesis of hepatocellular carcinoma.
Hepatitis B x antigen (HBx) is an important therapeutic target in the pathogenesis of hepatocellular carcinoma.
复制标题
B x抗原（HBx）是肝癌发病机制中的重要治疗靶点。
DOI：
10.18632/oncotarget.28077
复制
发表时间：
2021-11-23
期刊：
影响因子：
--
通讯作者：
Feitelson MA
中科院分区：
文献类型：
--
作者：
Medhat A;Arzumanyan A;Feitelson MA
乙肝病毒是一种人类病原体，全世界估计有20亿人感染。尽管有高效疫苗的出现，病毒血液供应的普遍筛查，以及有效的直接作用的抗病毒药物，但仍有超过2.5亿的乙肝病毒携带者面临着随后发展为肝炎、纤维化、肝硬化和肝细胞癌(HCC)的风险。每年有80多万人死于慢性乙肝。已经开发了许多不同的治疗方法来阻止病毒复制，虽然有效，但没有一种是治愈的。这些治疗对整合的HBVDNA部分影响很小或没有影响，该部分通常编码病毒调节蛋白HBx。尽管HBx很少受到关注，但它是一个重要的治疗靶点，因为它对(A)乙肝病毒的复制，(B)在慢性感染期间保护感染细胞免受免疫介导的破坏，以及(C)在肝细胞癌的发展中起着重要作用。因此，针对HBx的疗法的开发，与其他现有疗法相结合，将提供一种针对病毒复制的功能性疗法，并进一步降低或消除与慢性肝病和肝细胞癌相关的发病率和死亡率。同时针对所有这些特征，强调了开发针对HBx的治疗方法的重要性。
Hepatitis B virus (HBV) is a human pathogen that has infected an estimated two billion people worldwide. Despite the availability of highly efficacious vaccines, universal screening of the blood supply for virus, and potent direct acting anti-viral drugs, there are more than 250 million carriers of HBV who are at risk for the sequential development of hepatitis, fibrosis, cirrhosis and hepatocellular carcinoma (HCC). More than 800,000 deaths per year are attributed to chronic hepatitis B. Many different therapeutic approaches have been developed to block virus replication, and although effective, none are curative. These treatments have little or no impact upon the portions of integrated HBV DNA, which often encode the virus regulatory protein, HBx. Although given little attention, HBx is an important therapeutic target because it contributes importantly to (a) HBV replication, (b) in protecting infected cells from immune mediated destruction during chronic infection, and (c) in the development of HCC. Thus, the development of therapies targeting HBx, combined with other established therapies, will provide a functional cure that will target virus replication and further reduce or eliminate both the morbidity and mortality associated with chronic liver disease and HCC. Simultaneous targeting of all these characteristics underscores the importance of developing therapies against HBx.